Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

NCT03250377 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03250377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03250377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2017
Completion date
December 24, 2024
Enrollment
207 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, partial seizures with or without secondary generalization